Transphorm Announces Fiscal Fourth Quarter 2021 Financial Results
Transphorm, Inc. (TGAN) reported financial results for Q4 2021, showing a 20% sequential revenue increase to $2.4 million, up from $2.0 million in Q3 2021 and $1.1 million in Q4 2020. The full fiscal year 2021 revenue reached $12.7 million, slightly up from $12.5 million in FY 2020. Despite revenue growth, the company faced a GAAP net loss of ($6.6 million) for Q4 2021, widening from ($4.7 million) in the previous quarter. As of March 31, 2021, cash and equivalents were $9.5 million, down from $14.6 million a year prior.
- 20% sequential revenue increase to $2.4 million in Q4 2021.
- Full fiscal year 2021 revenue grew to $12.7 million from $12.5 million in 2020.
- Ongoing demand for GaN devices with new design wins secured.
- GAAP net loss widened to ($6.6 million) in Q4 2021, up from ($4.7 million) in Q3 2021.
- Full fiscal year 2021 GAAP net loss increased to ($20.3 million), from ($13.1 million) in FY 2020.
- Cash and equivalents decreased to $9.5 million from $14.6 million year-over-year.
Transphorm, Inc. (OTCQX: TGAN)—a pioneer in and global supplier of high reliability, high performance gallium nitride (GaN) power conversion products, today announced financial results for the company’s fiscal fourth quarter of 2021 ended March 31, 2021, which reflects the Company’s new fiscal year-end period.
Revenue for the fiscal fourth quarter of 2021 increased
Operating expenses on a GAAP basis were
GAAP net loss for the fiscal fourth quarter of 2021 was (
For the full fiscal year 2021, GAAP net loss was (
Cash and equivalents as of March 31, 2021 were
Commenting on the current fiscal first quarter of 2022, Transphorm’s President and Co-founder, Primit Parikh, stated, “Following our strong results and record product revenue in the March quarter, we have continued to secure new design wins and experience growing customer demand for Transphorm’s GaN power devices. Throughout the current quarter our team has been focused on ramping both volume production shipments and future capacity, and we remain on track toward our goal of having the capacity to ship more than 1 million GaN devices for Adapters per month by the end of calendar 2021. We are also continuing to leverage the field-proven reliability, quality and performance of Transphorm’s devices to extend our market leading position in GaN products for high-power applications, including gaming, crypto-mining and data centers – for which Transphorm’s latest Gen 5 product will also be commercially released in the coming quarter.”
Change of Fiscal Year
As previously announced, Transphorm recently completed the change of the Company’s fiscal year end from December 31 to March 31. This change was implemented as part of the Company’s preparations for a planned application to uplist to the Nasdaq Capital Market in the second half of calendar 2021.
Recent Business Update Conference Call
There will be no conference call associated with today’s press release. The Company encourages interested parties to access the previously hosted business update conference call held on Tuesday, May 18, 2021. A replay and the supporting presentation materials from the May 18 conference call is available in the Investors section of Transphorm’s website at www.transphormusa.com.
About Transphorm
Transphorm, Inc., a global leader in the GaN revolution, designs and manufactures high performance and high reliability GaN semiconductors for high voltage power conversion applications. Having one of the largest Power GaN IP portfolios of more than 1,000 owned or licensed patents, Transphorm produces the industry’s first JEDEC and AEC-Q101 qualified high voltage GaN semiconductor devices. The Company’s vertically integrated device business model allows for innovation at every development stage: design, fabrication, device, and application support. Transphorm’s innovations are moving power electronics beyond the limitations of silicon to achieve over
Non-GAAP Financial Measures
This press release includes and makes reference to certain non-GAAP financial measures. The presentation of this financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP.
Transphorm believes that the presentation of non-GAAP financial measures provides important supplemental information to management and investors regarding financial and business trends relating to the Company’s financial condition and results of operations. Transphorm believes that these non-GAAP financial measures provide additional insight into Transphorm’s ongoing performance and core operational activities and has chosen to provide these measures for more consistent and meaningful comparison between periods. These measures should only be used to evaluate Transphorm’s results of operations in conjunction with the corresponding GAAP measures. The non-GAAP results exclude the effect of stock-based compensation, depreciation, amortization and change in fair value of promissory note.
A reconciliation between GAAP and non-GAAP financial results is provided in the financial statements portion of this press release.
Forward-Looking Statements
This press release contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning the Company’s planned application to uplist to the Nasdaq Capital Market, the Company’s technology and anticipated product offerings, industry acceptance of GaN technology, and the Company’s pipeline and future anticipated growth. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “plan,” “believe,” “intend,” “look forward,” and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: risks related to Transphorm’s operations, such as additional financing requirements and access to capital; competition; the ability of Transphorm to protect its intellectual property rights; and other risks set forth in the Company’s filings with the Securities and Exchange Commission. Except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.
Transphorm, Inc. Condensed Consolidated Balance Sheets (audited) (in thousands except share and per share data) |
|||||||
|
March 31, 2021 |
|
December 31, 2020 |
||||
Assets |
|
|
|
||||
Current assets: |
|
|
|
||||
Cash and cash equivalents |
$ |
9,500 |
|
|
$ |
14,694 |
|
Accounts receivable, net, including related parties |
1,618 |
|
|
844 |
|
||
Inventory |
2,223 |
|
|
1,627 |
|
||
Prepaid expenses and other current assets |
953 |
|
|
1,061 |
|
||
Total current assets |
14,294 |
|
|
18,226 |
|
||
Property and equipment, net |
1,360 |
|
|
1,324 |
|
||
Goodwill |
1,302 |
|
|
1,397 |
|
||
Intangible assets, net |
914 |
|
|
988 |
|
||
Other assets |
274 |
|
|
291 |
|
||
Total assets |
$ |
18,144 |
|
|
$ |
22,226 |
|
|
|
|
|
||||
Liabilities, convertible preferred stock and stockholders’ deficit |
|
|
|
||||
Current liabilities: |
|
|
|
||||
Accounts payable and accrued expenses |
$ |
3,140 |
|
|
$ |
3,182 |
|
Deferred revenue |
505 |
|
|
674 |
|
||
Development loan |
10,000 |
|
|
10,000 |
|
||
Revolving credit facility, including accrued interest |
10,150 |
|
|
10,153 |
|
||
Unfunded commitment to joint venture |
1,866 |
|
|
1,466 |
|
||
Accrued payroll and benefits |
1,410 |
|
|
1,215 |
|
||
Total current liabilities |
27,071 |
|
|
26,690 |
|
||
Promissory note |
16,128 |
|
|
15,392 |
|
||
Total liabilities |
43,199 |
|
|
42,082 |
|
||
Total stockholders’ deficit |
(25,055 |
) |
|
(19,856 |
) |
||
Total liabilities and stockholders’ deficit |
$ |
18,144 |
|
|
$ |
22,226 |
|
Transphorm, Inc. Condensed Consolidated Statements of Operations (in thousands except share and per share data) |
|||||||||||||||
|
Three Months Ended March 31, |
|
Twelve Months Ended March 31, |
||||||||||||
|
2021
|
|
2020
|
|
2021
|
|
2020 (unaudited) |
||||||||
Revenue, net, including related parties |
$ |
2,425 |
|
|
$ |
1,100 |
|
|
$ |
12,696 |
|
|
$ |
12,505 |
|
Operating expenses: |
|
|
|
|
|
|
|
||||||||
Cost of goods sold |
1,788 |
|
|
1,455 |
|
|
7,015 |
|
|
6,543 |
|
||||
Research and development |
1,780 |
|
|
1,466 |
|
|
5,898 |
|
|
7,430 |
|
||||
Sales and marketing |
663 |
|
|
518 |
|
|
2,319 |
|
|
2,276 |
|
||||
General and administrative |
2,733 |
|
|
3,092 |
|
|
9,969 |
|
|
8,447 |
|
||||
Total operating expenses |
6,964 |
|
|
6,531 |
|
|
25,201 |
|
|
24,696 |
|
||||
Loss from operations |
(4,539 |
) |
|
(5,431 |
) |
|
(12,505 |
) |
|
(12,191 |
) |
||||
Interest expense |
187 |
|
|
189 |
|
|
758 |
|
|
760 |
|
||||
Loss in joint venture |
1,468 |
|
|
1,419 |
|
|
6,885 |
|
|
3,995 |
|
||||
Changes in fair value of promissory note |
699 |
|
|
(2,321 |
) |
|
2,093 |
|
|
(2,187 |
) |
||||
Other income, net |
(314 |
) |
|
(531 |
) |
|
(1,940 |
) |
|
(1,659 |
) |
||||
Loss before tax expense |
(6,579 |
) |
|
(4,187 |
) |
|
(20,301 |
) |
|
(13,100 |
) |
||||
Tax expense |
— |
|
|
— |
|
|
— |
|
|
— |
|
||||
Net loss |
$ |
(6,579 |
) |
|
$ |
(4,187 |
) |
|
$ |
(20,301 |
) |
|
$ |
(13,100 |
) |
Net loss per share - basic and diluted |
$ |
(0.16 |
) |
|
$ |
(0.13 |
) |
|
$ |
(0.56 |
) |
|
$ |
(0.45 |
) |
Weighted average common shares outstanding - basic and diluted |
40,274,660 |
|
|
31,912,170 |
|
|
36,571,712 |
|
|
29,093,258 |
|
||||
Transphorm, Inc. Condensed Consolidated Statements of Cash Flows (in thousands) |
|||||||
|
Three Months Ended March 31, |
||||||
|
2021
|
|
2020
|
||||
Cash flows from operating activities: |
|
|
|
||||
Net loss |
$ |
(6,579 |
) |
|
$ |
(4,187 |
) |
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
||||
Inventory write-off |
7 |
|
|
169 |
|
||
Depreciation and amortization |
197 |
|
|
236 |
|
||
Recovery from doubtful accounts |
(48 |
) |
|
— |
|
||
Stock-based compensation |
513 |
|
|
132 |
|
||
Interest cost |
187 |
|
|
189 |
|
||
Gain on sale of equipment |
(40 |
) |
|
— |
|
||
Loss in joint venture |
1,468 |
|
|
1,419 |
|
||
Changes in fair value of promissory note |
699 |
|
|
(2,321 |
) |
||
Changes in operating assets and liabilities: |
|
|
|
||||
Accounts receivable |
(690 |
) |
|
(668 |
) |
||
Inventory |
(603 |
) |
|
(264 |
) |
||
Prepaid expenses and other current assets |
108 |
|
|
(603 |
) |
||
Other assets |
17 |
|
|
9 |
|
||
Accounts payable and accrued expenses |
(195 |
) |
|
(179 |
) |
||
Deferred revenue |
(169 |
) |
|
— |
|
||
Accrued payroll and benefits |
195 |
|
|
(83 |
) |
||
Net cash used in operating activities |
(4,933 |
) |
|
(6,151 |
) |
||
Cash flows from investing activities: |
|
|
|
||||
Purchases of property and equipment |
(164 |
) |
|
— |
|
||
Investment in joint venture |
(968 |
) |
|
(1,548 |
) |
||
Net cash used in investing activities |
(1,132 |
) |
|
(1,548 |
) |
||
Cash flows from financing activities: |
|
|
|
||||
Proceeds from sale of equipment |
4 |
|
|
— |
|
||
Proceeds from stock option exercise |
2 |
|
|
18 |
|
||
Payment for repurchase of common stock |
— |
|
|
(211 |
) |
||
Loan repayment |
— |
|
|
(50 |
) |
||
Proceeds from issuance of common stock, net of offering cost |
950 |
|
|
19,741 |
|
||
Net cash provided by financing activities |
956 |
|
|
19,498 |
|
||
Effect of foreign exchange rate changes on cash and cash equivalents |
(85 |
) |
|
(26 |
) |
||
Net (decrease) increase in cash and cash equivalents |
(5,194 |
) |
|
11,773 |
|
||
Cash and cash equivalents at beginning of period |
14,694 |
|
|
2,875 |
|
||
Cash and cash equivalents at end of period |
$ |
9,500 |
|
|
$ |
14,648 |
|
|
|
|
|
||||
Supplemental disclosures of cash flow information: |
|
|
|
||||
Interest expense paid |
$ |
153 |
|
|
$ |
— |
|
Supplemental non-cash financing activity: |
|
|
|
||||
Conversion of preferred stock to common stock in connection with the Reverse Merger |
$ |
— |
|
|
$ |
85,658 |
|
Transphorm, Inc. Reconciliation of GAAP and Non-GAAP Financial Information (unaudited) (in thousands except share and per share data) |
|||||||||||||||||||
Three Months Ended |
Twelve Months Ended |
||||||||||||||||||
|
March 31, |
December 31, |
March 31, |
|
March 31, |
March 31, |
|||||||||||||
|
2021 |
2020 |
2020 |
|
2021 |
2020 |
|||||||||||||
GAAP net loss |
$ |
(6,579 |
) |
$ |
(4,712 |
) |
$ |
(4,187 |
) |
|
$ |
(20,301 |
) |
$ |
(13,100 |
) |
|||
Adjustments: |
|
|
|
|
|
|
|||||||||||||
Stock based compensation |
|
513 |
|
|
705 |
|
|
132 |
|
|
|
1,906 |
|
|
555 |
|
|||
Depreciation |
|
123 |
|
|
130 |
|
|
133 |
|
|
|
499 |
|
|
553 |
|
|||
Amortization |
|
74 |
|
|
74 |
|
|
103 |
|
|
|
296 |
|
|
593 |
|
|||
Changes in fair value of promissory note |
|
699 |
|
|
(927 |
) |
|
(2,321 |
) |
|
|
2,093 |
|
|
(2,187 |
) |
|||
Total adjustments to GAAP net loss |
|
1,409 |
|
|
(18 |
) |
|
(1,953 |
) |
|
|
4,794 |
|
|
(486 |
) |
|||
Non-GAAP net loss |
|
(5,170 |
) |
|
(4,730 |
) |
|
(6,140 |
) |
|
|
(15,507 |
) |
|
(13,586 |
) |
|||
|
|
|
|
|
|
|
|||||||||||||
GAAP net loss per share - basic and diluted |
$ |
(0.16 |
) |
$ |
(0.13 |
) |
$ |
(0.13 |
) |
|
$ |
(0.56 |
) |
$ |
(0.45 |
) |
|||
Adjustment |
|
0.03 |
|
|
- |
|
|
(0.06 |
) |
|
|
0.14 |
|
|
(0.02 |
) |
|||
Non-GAAP net loss per share - basic and diluted |
$ |
(0.13 |
) |
$ |
(0.13 |
) |
$ |
(0.19 |
) |
|
$ |
(0.42 |
) |
$ |
(0.47 |
) |
|||
Weighted average shares outstanding - basic and diluted |
|
40,274,660 |
|
|
35,719,749 |
|
|
31,912,170 |
|
|
|
36,571,712 |
|
|
29,093,258 |
|
|||
|
|
|
|
|
|
|
|||||||||||||
|
Three Months Ended |
|
Twelve Months Ended |
||||||||||||||||
|
March 31, |
December 31, |
March 31, |
|
March 31, |
March 31, |
|||||||||||||
|
2021 |
2020 |
2020 |
|
2021 |
2020 |
|||||||||||||
GAAP Operating Expense |
$ |
5,176 |
|
$ |
4,524 |
|
$ |
5,076 |
|
|
$ |
18,186 |
|
$ |
18,153 |
|
|||
Adjustments: |
|
|
|
|
|
|
|||||||||||||
Stock based compensation |
|
475 |
|
|
657 |
|
|
116 |
|
|
|
1,790 |
|
|
493 |
|
|||
Depreciation |
|
123 |
|
|
130 |
|
|
133 |
|
|
|
499 |
|
|
553 |
|
|||
Amortization |
|
74 |
|
|
74 |
|
|
103 |
|
|
|
296 |
|
|
593 |
|
|||
Total adjustments to GAAP Operating Expense |
|
672 |
|
|
861 |
|
|
352 |
|
|
|
2,585 |
|
|
1,639 |
|
|||
Non-GAAP Operating Expense |
$ |
4,504 |
|
$ |
3,663 |
|
$ |
4,724 |
|
|
|
15,601 |
|
|
16,514 |
|
|||
|
|
|
|
|
|
|
|||||||||||||
View source version on businesswire.com: https://www.businesswire.com/news/home/20210624005336/en/
FAQ
What were Transphorm's Q4 2021 financial results?
What is Transphorm's revenue for the full fiscal year 2021?
How did Transphorm's cash position change by March 31, 2021?
What are Transphorm's expectations for future revenue growth?
